Literature DB >> 30536795

Withholding and withdrawing treatment for cost-effectiveness reasons: Are they ethically on par?

Lars Sandman1, Jan Liliemark1.   

Abstract

In healthcare priority settings, early access to treatment before reimbursement decisions gives rise to problems of whether negative decisions for cost-effectiveness reasons should result in withdrawing treatment, already accessed by patients. Among professionals there seems to be a strong attitude to distinguish between withdrawing and withholding treatment, viewing the former as ethically worse. In this article the distinction between withdrawing and withholding treatment for reasons of cost effectiveness is explored by analysing the doing/allowing distinction, different theories of justice, consequentialist and virtue perspectives. The authors do not find any strong reasons for an intrinsic difference, but do find some reasons for a consequentialist difference, given present attitudes. However, overall, such a difference does not, all things considered, provide a convincing reason against withdrawal, given the greater consequentialist gain of using cost-effective treatment. As a result, patients should be properly informed when given early access to treatment, that such treatment can be later withdrawn following a negative reimbursement decision.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  cost effectiveness; equivalence thesis; priority setting; withdrawing; withholding

Mesh:

Year:  2018        PMID: 30536795     DOI: 10.1111/bioe.12545

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  2 in total

1.  Withdrawing or withholding treatments in health care rationing: an interview study on ethical views and implications.

Authors:  Liam Strand; Lars Sandman; Gustav Tinghög; Ann-Charlotte Nedlund
Journal:  BMC Med Ethics       Date:  2022-06-24       Impact factor: 2.834

2.  What influences the outcome of active disinvestment processes in healthcare? A qualitative interview study on five recent cases of active disinvestment.

Authors:  Adriënne H Rotteveel; Mattijs S Lambooij; Joline J A van de Rijt; Job van Exel; Karel G M Moons; G Ardine de Wit
Journal:  BMC Health Serv Res       Date:  2021-04-01       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.